Page 228 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer

Addendum
• Jauw YWS, Menke-van der Houven van Oordt CW, Hoekstra OS, Hendrikse NH, Vugts DJ, Zijlstra JM, Huisman MC, van Dongen GA. Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials? Front Pharmacol. 2016 May 24;7:131. doi: 10.3389/fphar.2016.00131.
• Keizer S, Gerritsen R, Jauw Y, Janssen J, Koopman B, Bresser P. Fatal tuberculosis during treatment with ruxolitinib. Ned Tijdschr Geneeskd. 2015;159:A8650.
• Wondergem MJ, Rizvi SN, Jauw Y, Hoekstra OS, Hoetjes N, van de Ven PM, Boellaard R, Chamuleau ME, Cillessen SA, Regelink JC, Zweegman S, Zijlstra JM. 18F-FDG or 3’-deoxy-3’-18F-fluorothymidine to detect transformation of follicular lymphoma. J Nucl Med. 2015 Feb;56(2):216-21. doi: 10.2967/ jnumed.114.149625.
• de Jong A, Kwee TC, de Klerk JM, Adam JA, de Keizer B, Fijnheer R, Kersten MJ, Ludwig I, Jauw YW, Zijlstra JM, Pieters-Van den Bos IC, Stoker J, Hoekstra OS, Nievelstein RA. Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma. Am J Nucl Med Mol Imaging. 2014 Apr 25;4(3):231-8.
• Börjesson PK, Jauw YW, de Bree R, Roos JC, Castelijns JA, Leemans CR, van Dongen GA, Boellaard R. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009 Nov ;50(11):1828-36. doi: 10.2967/jnumed.109.065862.
• Börjesson PK, Jauw YW, Boellaard R, de Bree R, Comans EF, Roos JC, Castelijns JA, Vosjan MJ, Kummer JA, Leemans CR, Lammertsma AA, van Dongen GA. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2133-40.
226